Last reviewed · How we verify
Typhoid Vaccine
Typhoid Vaccine is a vaccine Biologic drug developed by University of Oxford. It is currently FDA-approved for Prevention of typhoid fever in endemic regions and travelers. Also known as: Typhim Vi®, Typhim Vi, Typhoid Vi Polysaccharide Vaccine.
The typhoid vaccine stimulates the immune system to produce antibodies and cellular immunity against Salmonella typhi, the bacterium that causes typhoid fever.
The Typhoid Vaccine is a vaccine component that targets Salmonella Typhi, a bacterium causing typhoid fever. It has been studied in clinical trials, including a Phase 2a study evaluating its safety, reactogenicity, and immune response against invasive nontyphoidal Salmonella disease and typhoid fever in infants.
At a glance
| Generic name | Typhoid Vaccine |
|---|---|
| Also known as | Typhim Vi®, Typhim Vi, Typhoid Vi Polysaccharide Vaccine |
| Sponsor | University of Oxford |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains either live attenuated (weakened) or inactivated typhoid bacteria, or purified polysaccharide capsular antigen, which triggers both humoral and cell-mediated immune responses. This allows the body to recognize and mount a rapid defense against natural infection with S. typhi, preventing or reducing the severity of typhoid disease.
Approved indications
- Prevention of typhoid fever in endemic regions and travelers
Common side effects
- Injection site pain or swelling
- Fever
- Headache
- Myalgia
- Gastrointestinal upset (oral formulation)
Key clinical trials
- Blood Donor CVD 5000 (PHASE4)
- Vellore Typhoid Vaccine Impact Trial (PHASE4)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Vaccine- and Infection-derived Correlates of Protection for Cholera. (NA)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults (PHASE4)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Typhoid Vaccine CI brief — competitive landscape report
- Typhoid Vaccine updates RSS · CI watch RSS
- University of Oxford portfolio CI
Frequently asked questions about Typhoid Vaccine
What is Typhoid Vaccine?
How does Typhoid Vaccine work?
What is Typhoid Vaccine used for?
Who makes Typhoid Vaccine?
Is Typhoid Vaccine also known as anything else?
What drug class is Typhoid Vaccine in?
What development phase is Typhoid Vaccine in?
What are the side effects of Typhoid Vaccine?
Related
- Drug class: All vaccine drugs
- Manufacturer: University of Oxford — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Prevention of typhoid fever in endemic regions and travelers
- Also known as: Typhim Vi®, Typhim Vi, Typhoid Vi Polysaccharide Vaccine
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing